Evidence map›Paper›PMID 36190039›Full record

ArticleIndian journal of ophthalmology2022

Smruti Rekha Priyadarshini, Tanvi Soni, Srikant Kumar Sahu, Amrita Mohanty, Savitri Sharma, Sanchita Mitra, Mohammad Hasnat Ali, Sujata Das

Open access · diamondAbstract read
In one paragraph

Article in Indian journal of ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Mycobiology · 2025
    Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Smruti Rekha PriyadarshiniCornea and Anterior Segment Service, L V Prasad Eye Institute, Bhubaneswar, Odisha, India.
Tanvi SoniCornea and Anterior Segment Service, L V Prasad Eye Institute, Bhubaneswar, Odisha, India.
Srikant Kumar SahuCornea and Anterior Segment Service, L V Prasad Eye Institute, Bhubaneswar, Odisha, India.
Amrita MohantyCornea and Anterior Segment Service, L V Prasad Eye Institute, Bhubaneswar, Odisha, India.
Savitri SharmaJhaveri Microbiology Center, L V Prasad Eye Institute, Hyderabad, Telangana, India.
Sanchita MitraOcular Microbiology Service, L V Prasad Eye Institute, Bhubaneswar, Odisha, India.
Mohammad Hasnat AliDepartment of Biostatistics, L V Prasad Eye Institute, Hyderabad, Telangana, India.
Sujata DasCornea and Anterior Segment Service, L V Prasad Eye Institute, Bhubaneswar, Odisha, India.
L V Prasad Eye Institute · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To study the risk factors, clinical presentation, management options, and outcomes in cases of culture-proven Acremonium keratitis. Methods: Medical and microbiology records of culture-proven Acremonium keratitis from Jan 2007 to Dec 2019 at a tertiary eye care center were reviewed. Details of clinical findings on each visit and operating notes were reviewed from the medical records. All cases were subjected to corneal scraping at the first visit for microbiological investigation consisting of direct smear examination and culture. Topical natamycin 5% was the mainstay of medical treatment. Surgical treatment was considered for nonresponding patients. Results: During the 13-year study period, 65 cases of culture-proven Acremonium keratitis were identified out of 1605 cases of fungal keratitis. Trauma was the most common predisposing factor in 32 cases (49.2%). The average area of the corneal stromal infiltrate was 24.8 mm Conclusion: When treated early, Acremonium keratitis responds well to medical therapy with currently available topical antifungals. However, advanced and nonresponding cases require surgical intervention for resolution of the infection.

Indexed as

AcremoniumCorneal DiseasesEye Infections, FungalKeratitisAntifungal AgentsHumansMiddle AgedNatamycinRetrospective StudiesRisk FactorsAntifungal AgentsNatamycincorneal infectionmicrobial keratitis

Identifiers

PMID36190039
PMCPMC9789801
OpenAlexW4300690824

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.